<?xml version="1.0" encoding="UTF-8"?>
<p>According to many reports, the COVID-19 patients are at high risk for venous thromboembolism, a term that associates deep vein thrombosis (DVT) [
 <xref rid="B119-ijerph-17-05904" ref-type="bibr">119</xref>]. In this context, patients are treated prophylactically by giving low molecular weight heparin (LMWH), when multiple risk factors exist. Hence, hospitalized COVID-19 patients are generally treated with higher doses of LMWH than recommended for thromboprophylaxis [
 <xref rid="B120-ijerph-17-05904" ref-type="bibr">120</xref>]. A recent document by the Italian Drug Agency (AIFA) suggested the use of 80 to 100 mg enoxaparin daily, instead of the usual 40 mg, while in some hospitals, even higher, up to full anticoagulant doses of LMWH or unfractionated heparin are used [
 <xref rid="B121-ijerph-17-05904" ref-type="bibr">121</xref>].
</p>
